Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A triple-agonist peptide investigated in clinical trials for metabolic and body-composition endpoints. One of the most-studied next-generation incretin candidates.
Evidence at a glance: Includes human-trial data
The cited record for this compound includes human-trial data. Each claim below still states its study type and population, so the scope of that evidence stays explicit.
Molecular identity
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
- CAS number
- 2381089-83-2
- Amino acids
- 39
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 99.2%
Researched mechanism
Acts as an agonist at GLP-1, GIP, and glucagon receptors simultaneously; the added glucagon activity is the primary point of research interest versus dual agonists.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Studied for significant body-weight change over 48 weeks in a phase 2 program.
Triple-receptor pharmacology characterized in receptor-binding and preclinical models.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Tirzepatide | Receptor targets | Retatrutide adds glucagon-receptor activity to the GLP-1/GIP profile. |
| Semaglutide | Mechanism | Semaglutide is GLP-1 only; retatrutide is a triple agonist. |
Retatrutide vial research model
Published study charts, concentration and supply calculations, with an interactive preparation model.
Open the full reference →Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 10 mg | 2 mL | 5 mg/mL |
| 20 mg | 2 mL | 10 mg/mL |
| 30 mg | 2 mL | 15 mg/mL |
| 60 mg | 2 mL | 30 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
What vial sizes are available?+
10 mg, 20 mg, and 30 mg lyophilized vials, each with a lot-specific COA.
How is it shipped?+
Lyophilized, with an insulated cold pack, tracked. Reconstitute on arrival or keep frozen.
